• 1
    Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89100.
  • 2
    Ubaid-Girioli S, Ferreira-Melo SE, Souza LA, et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(10):770774.
  • 3
    Christ M, Grimm W, Maisch B. [Significance of aldosterone antagonist therapy]. Internist. (Berl) 2004;45(3):347354.
  • 4
    Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25(4):891894.
  • 5
    Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839845.
  • 6
    Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(1):1924.
  • 7
    Pimenta E, Gaddam KK, Oparil S, et al. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(3):239244.
  • 8
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25): e510e526.
  • 9
    Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925930.
  • 10
    Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18(12 Pt 1):16311635.
  • 11
    Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci. 2007;113(6):267278.
  • 12
    Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):11591164.
  • 13
    Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34(9):944949.
  • 14
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):6774.
  • 15
    De Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, et al. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm. 2007;64(18):19551961.
  • 16
    Brazilian Society of Cardiology (SBC), Brazilian Society of Hypertension (SBH), Brazilian Society of Nephrology (SBN). V Brazilian Guidelines in Arterial Hypertension. Arq Bras Cardiol. 2007;89(3):2479.
  • 17
    Alessi A, Brandão AA, Pierin A, et al. Brazilian Society of Cardiology (SBC), Brazilian Society of Hypertension (SBH), Brazilian Society of Nephrology (SBN). IV Guideline for Ambulatory Blood Pressure Monitoring. II Guideline for Home Blood Pressure Monitoring. Arq Bras Cardiol. 2005;85(2):118.
  • 18
    Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257265.
  • 19
    Sahn DJ, De Maria A, Kisslo J, et al. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58(6):10721083.
  • 20
    Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):14401463.
  • 21
    Khouri SJ, Maly GT, Suh DD, et al. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr. 2004;17(3):290297.
  • 22
    Brennan RL, Prediger DJ. Coefficient kappa: some uses, misuses, and alternatives. Educ Psychol Meas. 1981;41(3):687699.
  • 23
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):25602572.
  • 24
    Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006;29(4):211216.
  • 25
    Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. BMC Cardiovasc Disord. 2007;7:14.
  • 26
    Chigogidze T, Simonia G. Flow-mediated dilation in patients with left ventricular diastolic dysfunction. Georgian Med News. 2005;128:4448.
  • 27
    Salles GF, Fiszman R, Cardoso CR, et al. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723728.
  • 28
    Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs. 2002;62(5):723731.
  • 29
    Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(1):1318.
  • 30
    Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42(1):4955.
  • 31
    Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37(6):14441449.
  • 32
    Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109(23):28572861.
  • 33
    Vasan RS, Evans JC, Benjamin EJ, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension. 2004;43(5):957962.
  • 34
    Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res. 2002;25(6):837842.
  • 35
    Taniguchi I, Kawai M, Date T, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J. 2006;70(8):9951000.
  • 36
    Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002;20(2):159169.
  • 37
    Hollander M, Hak AE, Koudstaal PJ, et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke. 2003;34(10):23672372.
  • 38
    Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19(11):19811989.
  • 39
    Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9(5):353359.